



IFW 1645

PATENT  
Attorney Reference Number 6565-72815-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Emily Li Chuan Tan, et al.

**Application No.** 10/560,198

**Filed:** December 8, 2005

**Confirmation No.** 3211

**For:** INHIBITION OF SARS CORONAVIRUS  
INFECTION WITH CLINICALLY  
APPROVED ANTIVIRAL DRUGS

**Examiner:** Louise Wang Zhiying Humphrey

**Art Unit:** 1645

**Attorney Reference No.** 6565-72815-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Date Mailed January 11, 2007

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and references cited thereon
- ☒ The Director is hereby authorized to charge any fees that may be required to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

Richard J. Polley  
Registration No. 28,107

cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: )  
 )  
Emily Li Chuan Tan and )  
Lawrence W. Stanton ) Group Art Unit: 1645  
 )  
Serial No.: 10/560,198 )  
 )  
Filed: December 8, 2005 ) Examiner: Unknown  
 )  
 ) Attorney Docket: 6565-72815-01/RJP  
 )  
For: INHIBITION OF SARS CORONA VIRUS )  
INFECTION WITH CLINICALLY )  
APPROVED ANTIVIRAL DRUGS )

PTO Customer No. 24197

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450  
U.S.A.

Dear Sir:

In accordance with the provisions of 37 CFR 1.56, Applicant hereby makes of record the references set out on the attached forms PTO/SB/08A and PTO/SB/08B.

A copy of the non-patent literature documents are enclosed.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103, and Applicant reserves the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish otherwise. Moreover, Applicant does not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

In re the application of:

Emily Li Chuan Tan and Lawrence W. Stanton


For: INHIBITION OF SARS CORONA VIRUS INFECTION WITH  
CLINICALLY APPROVED ANTIVIRAL DRUGS

- Page 2 -

It is respectfully requested that the information be expressly considered by the Examiner and that the references be made of record and appear among the "References Cited" on any patent to issue therefrom.

The Patent Office is hereby authorized to charge any deficiency, or credit any overpayment in fees to deposit account no. 19-2548.

Respectfully submitted,

  
Richard J. Polley  
Registration No. 28,107

KLARQUIST SPARKMAN LLP  
One World Trade Center  
121 S.W. Salmon Street, Suite 1600  
Portland, Oregon 97204  
Tel: (503) 226-7391  
Fax: (503) 228-9446

January 11, 2007  
Date

Enclosures  
92337-16 (SAH/kdr/kep)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/560,198
Filing Date	December 8, 2005
First Named Inventor	Emily Li Chuan Tan
Art Unit	1645
Examiner Name	
Attorney Docket Number	6565-72815-01/RJP

Sheet	1	of	4
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/560,198
Filing Date	December 8, 2005
First Named Inventor	Emily Li Chuan Tan
Art Unit	1645
Examiner Name	
Attorney Docket Number	6565-72815-01/RJP

Sheet

2

of

4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		World Health Organization. Acute respiratory syndrome in China—update 3: disease outbreak reported: Geneva: The Organization; 2003.	
		LEE, N., HUI, D.H., WU, A., CHAN, P., CAMERON, P., JOYNT, G.M., ET AL. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1986–94.	
		KSIAZEK, T.G., ERDMAN, D., GOLDSMITH, C., ZAKI, S.R., PERET, T., EMERY, S., ET AL. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1953–66.	
		TSANG, K.W., HO, P.L., OOI, G.C., YEE, W.K., WANG, T., CHAN-YEUNG, M., ET AL. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1977–85.	
		Severe acute respiratory syndrome (SARS) and coronavirus testing—United States, 2003. Morb Mortal Wkly Rep 2003, 52:297–302.	
		PEIRIS, J.S.M., CHU, C.M., CHENG, V.C., CHAN, K.S., HUNG, I.F., POON, L.L., ET AL. Clinical progression and viral load in a community outbreak of coro-navirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361:1767–72.	
		CHAN-YEUNG, M., YU, W.C. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report. BMJ 2003, 326:850–2.	
		NICHOLLS, J.M., POON, L.L., LEE, K.C., NG, W.F., LAI, S.T., LEUNG, C.Y., ET AL. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003, 361:1773–8.	
		POUTANEN, S.M., LOW, D.E., HENRY, B., FINKELSTEIN, S., ROSE, D., GREEN, K., ET AL. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003, 348:1995–2005.	
		DROSTEN, C., GUNTHER, S., PREISER, W., VAN DER WERF, S., BRODT, H.R., BECKER, S., ET AL. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003, 348:1967–76.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet <b>3</b> of <b>4</b>	Application Number	10/560,198
	Filing Date	December 8, 2005
	First Named Inventor	Emily Li Chuan Tan
	Art Unit	1645
	Examiner Name	
Attorney Docket Number		6565-72815-01/RJP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LAPINSKY, S.E. and HAWRYLUK, L. ICU management of severe acute respiratory syndrome. Intensive Care Med 2003, 29:870-5.	
		BOOTH, C.M., MATUKAS, L.M., TOMLINSON, G.A., RACHLIS, A.R., ROSE, D.B., DWOSH, H.A., ET AL. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289:2801-9. Erratum in: JAMA 2003, 290:334.	
		DRISCOLL, J.S. Antiviral drugs. Aldershot, UK: Ashgate Publishing Ltd, 2002.	
		RUAN, Y.J., WEI, C.L., EE, A.L., VEGA, V.B., THOREAU, H., SU, S.T., ET AL. Comparative full length genome sequence analysis of 14 SARS coro-navirus isolates and common mutations associated with putative origins of infection. Lancet 2003, 361:1779-85. Erratum in: Lancet 2003, 361:1832.	
		RICHMOND, J.Y. and MCKINNEY, R.W. Biosafety in microbiological and bio-medical laboratories. 4th ed. Washington: U.S. Government Printing Office, 1999.	
		AL-JABRI, A.A., WIGG, M.D. and OXFORD, J.S. Initial in vitro screening of drug candidates for their potential antiviral activities. In: Mahy, B.W.J. and Kangro H.O. eds. Virology Methods Manual. Academic Press Ltd. London. 1996: 293-356.	
		HUFFMAN, J.H., SIDWELL, R.W., KHARE, G.P., ET AL. In vitro effect of 1-beta-D- ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN-1229) on deoxy-ribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemo. 1973, 3:235-241.	
		SAGANUMA, T. and ISHIDA, N. An evaluation of a new antiviral agent 'Virazole' against influenza virus infections. Tohoku J. Exp. Med. 1973, 110: 405-406.	
		MORREY, J.D., SMEE, D.F., SIDWELL, R.W., and TSENG, C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002, 55:107-16.	
		DAVIS, G.L., ET AL. Interferon alpha2b alone or in combination with Ribavirin for the treatment of relapse of chronic hepatitis. N. Engl. J. Med. 1998, 339:1493-1499.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Application Number</b>		10/560,198		
	<b>Filing Date</b>		December 8, 2005		
	<b>First Named Inventor</b>		Emily Li Chuan Tan		
	<b>Art Unit</b>		1645		
	<b>Examiner Name</b>				
<b>Sheet</b>	4	of	4	<b>Attorney Docket Number</b>	6565-72815-01/RJP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		POYNARD, T.P., ET AL. Randomised trial for interferon alpha2b plus Ribavirin. Lancet 1998, 352;1426-1432.	
		MCHUTCHISON, J.G., ET AL. Interferon alpha2b alone or in combination with Ribavirin as initial treatment for hepatitis C. N. Engl. J. Med. 1998, 339:1485-1492.	
		PFEFFER, L.M., ET AL. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998, 58:2489-2499.	
		LEE, C.K., BLUYSSSEN, H.A. and LEVY, D.E. Regulation of interferon alpha responsiveness by the duration of Janus kinase activity J. Biol. Chem. 1997, 272:21872-21877.	
		TURNER, R.B., FELTON, A., KOSAK, K., KELSEY, D.K., and MESCHIEVITZ, C.K. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 1986; 154:443-7.	
		HIGGINS, P.G., PHILLPOTTS, R.J., SCOTT, G.M., WALLACE, J., BERNHARDT, L.L., and TYRRELL, D.A. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24:713-5.	
		TYRELL, D.A. The efficacy and tolerance of intranasal interferons: studies at the common cold unit. J Antimicrob Chemother 1986; 18B:153-6.	
		WEINGARTL, H.M., and DERBYSHIRE, J.B. Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta. Can J Vet Res 1991; 55:143-9.	
		JORDAN, L.T., and DERBYSHIRE, J.B. Antiviral activity of interferon against transmissible gastroenteritis virus in cell culture and ligated intestinal segments in neonatal pigs. Vet Microbiol 1994; 38:263-76.	
		TAN, EMILY L.C., ET AL. Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs. Emerging Infections Diseases. April 2004. Volume 10, No. 4. Pages 581-586.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.